DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Diphtheria - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Diphtheria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with the latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diphtheria and special features on late-stage and discontinued projects.
The report enhances decision-making capabilities and helps to create effective counter-strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Diphtheria Overview
- Therapeutics Development
- Pipeline Products for Diphtheria - Overview
- Pipeline Products for Diphtheria - Comparative Analysis
- Diphtheria - Therapeutics under Development by Companies
- Diphtheria - Therapeutics under Investigation by Universities/Institutes
- Diphtheria Products Glance
- Late-Stage Products
- Clinical-Stage Products
- Early-Stage Products
- Diphtheria - Products under Development by Companies
- Diphtheria - Products under Investigation by Universities/Institutes
- Diphtheria - Companies Involved in Therapeutics Development
- Beijing Minhai Biotechnology Co., Ltd.
- Biological E. Limited
- Boryung Pharmaceutical Co., Ltd.
- Daiichi Sankyo Company, Limited
- GlaxoSmithKline Plc
- Green Cross Corporation
- Indian Immunologicals Limited
- LG Life Science Ltd.
- Panacea Biotec Limited
- Prometheon Pharma, LLC
- Sanofi Pasteur SA
- Serum Institute of India Limited
- Sinovac Biotech Ltd.
- Zydus Cadila Healthcare Limited
For more information visit http://www.researchandmarkets.com/research/rzmwwk/diphtheria.
